Tumour necrosis factor alpha kinoid

Drug Profile

Tumour necrosis factor alpha kinoid

Alternative Names: TNF-K; TNF-K005; TNFα-kinoid

Latest Information Update: 18 Aug 2015

Price : $50

At a glance

  • Originator Neovacs
  • Class Antirheumatics; Antiulcers; Vaccines
  • Mechanism of Action Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Suspended Crohn's disease; Rheumatoid arthritis

Most Recent Events

  • 26 Jun 2015 Suspended - Phase-I/II for Crohn's disease in South Africa and Switzerland (IM)
  • 26 Jun 2015 Suspended - Phase-II for Crohn's disease in Belgium, Bulgaria, Croatia, Czech Republic, France, Germany, Hungary, Netherlands and Romania (IM)
  • 26 Jun 2015 Suspended - Phase-II for Rheumatoid arthritis in Argentina, Belgium, Bulgaria, Chile, Croatia, Czech Republic, France, Georgia, Hungary, Lebanon, Macedonia, Moldova, Poland, Romania, Russia, Serbia and Ukraine (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top